DE60001271T2 - Hydroxymatairesinol in der krebs-prevention - Google Patents
Hydroxymatairesinol in der krebs-preventionInfo
- Publication number
- DE60001271T2 DE60001271T2 DE60001271T DE60001271T DE60001271T2 DE 60001271 T2 DE60001271 T2 DE 60001271T2 DE 60001271 T DE60001271 T DE 60001271T DE 60001271 T DE60001271 T DE 60001271T DE 60001271 T2 DE60001271 T2 DE 60001271T2
- Authority
- DE
- Germany
- Prior art keywords
- hydroxymatairesinol
- person
- cancer
- prevention
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- UKHWOLNMBQSCLJ-BIENJYKASA-N hydroxymatairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@H]2C(OC[C@@H]2[C@H](O)C=2C=C(OC)C(O)=CC=2)=O)=C1 UKHWOLNMBQSCLJ-BIENJYKASA-N 0.000 title abstract 5
- YNOCUODOFOEIFZ-UHFFFAOYSA-N Hydroxymatairesinol Natural products C1=C(O)C(OC)=CC=C1CC1C(=O)OCC1C(O)C1=CC=C(OC)C(O)=C1 YNOCUODOFOEIFZ-UHFFFAOYSA-N 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 abstract 1
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 239000002778 food additive Substances 0.000 abstract 1
- 235000013373 food additive Nutrition 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/281,094 US6451849B1 (en) | 1999-03-30 | 1999-03-30 | Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol |
| PCT/FI2000/000181 WO2000059946A1 (en) | 1999-03-30 | 2000-03-09 | Hydroxymatairesinol in cancer prevention |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60001271D1 DE60001271D1 (de) | 2003-02-27 |
| DE60001271T2 true DE60001271T2 (de) | 2003-07-31 |
Family
ID=23075932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60001271T Expired - Lifetime DE60001271T2 (de) | 1999-03-30 | 2000-03-09 | Hydroxymatairesinol in der krebs-prevention |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6451849B1 (de) |
| EP (1) | EP1165537B1 (de) |
| JP (2) | JP4852685B2 (de) |
| KR (2) | KR100741724B1 (de) |
| CN (1) | CN1146553C (de) |
| AT (1) | ATE231500T1 (de) |
| AU (1) | AU767691B2 (de) |
| BG (1) | BG65380B1 (de) |
| BR (1) | BR0007187A (de) |
| CA (2) | CA2371839C (de) |
| CZ (2) | CZ302730B6 (de) |
| DE (1) | DE60001271T2 (de) |
| DK (1) | DK1165537T3 (de) |
| EE (1) | EE200100507A (de) |
| ES (1) | ES2189738T3 (de) |
| HK (1) | HK1045992B (de) |
| HU (1) | HUP0200530A3 (de) |
| MX (1) | MXPA01009714A (de) |
| NO (4) | NO330135B1 (de) |
| NZ (1) | NZ512099A (de) |
| PL (1) | PL199892B1 (de) |
| RU (1) | RU2241453C2 (de) |
| SK (2) | SK287001B6 (de) |
| WO (1) | WO2000059946A1 (de) |
| ZA (1) | ZA200104440B (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6271257B1 (en) * | 2000-04-17 | 2001-08-07 | Hormos Nutraceutical Oy Ltd. | Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol |
| WO2002034277A1 (en) * | 2000-10-23 | 2002-05-02 | Council Of Scientific And Industrial Research | Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara |
| EP1428015A4 (de) * | 2001-08-16 | 2008-09-17 | Analiza Inc | Verfahren zur löslichkeitsmessung |
| WO2003042694A2 (en) * | 2001-11-12 | 2003-05-22 | Analiza, Inc. | Characterization of molecules |
| FI111638B (fi) * | 2001-11-23 | 2003-08-29 | Hormos Nutraceutical Oy Ltd | Menetelmä hydroksimatairesinolin tuottamiseksi puusta |
| US7008666B2 (en) * | 2001-11-26 | 2006-03-07 | Hormos Nutraceutical Oy Ltd. | Method of inhibiting overactivity of phagocytes or lymphocytes in an individual |
| US20030144216A1 (en) * | 2002-01-25 | 2003-07-31 | Mikko Unkila | Method for prevention of diseases in coeliac patients |
| WO2003066556A1 (en) * | 2002-02-05 | 2003-08-14 | Hormos Medical Corporation | Lignan derivatives |
| US7048960B2 (en) * | 2002-03-22 | 2006-05-23 | Glenn Roy Pizzey | High lignan flaxseed product and product by process |
| FI20021184A (fi) | 2002-06-19 | 2003-12-20 | Hormos Nutraceutical Oy Ltd | Lignaanivalmisteita |
| FI114917B (fi) * | 2002-08-29 | 2005-01-31 | Hormos Nutraceutical Oy Ltd | Lignaanikomplekseja |
| FR2851919A1 (fr) * | 2003-03-03 | 2004-09-10 | Lmd | Lignanes utilisables comme inhibiteurs de cathepsines et leurs applications |
| US8099242B2 (en) * | 2003-06-12 | 2012-01-17 | Analiza, Inc. | Systems and methods for characterization of molecules |
| FI116727B (sv) | 2003-11-12 | 2006-02-15 | Arbonova Ab Oy | Ny användning för kvistnötsextrakt |
| US7976877B2 (en) | 2003-11-12 | 2011-07-12 | Oy Arbonova Ab | Use of knotwood extracts |
| CN1893939B (zh) * | 2003-12-26 | 2011-12-28 | 农工大Tlo株式会社 | 用于预防和治疗肝癌的组合物 |
| KR100739280B1 (ko) * | 2004-02-03 | 2007-07-12 | 가부시끼가이샤 고또스기 | 운남 홍두삼 유래 이소탁시레시놀을 성분으로 하는골다공증 치료ㆍ예방약 |
| BRPI0519851A2 (pt) * | 2005-01-10 | 2017-05-30 | Hormos Medical Ltd | uso de uma lignana para a manufatura de uma composição para prevenir ou aliviar os sintomas relacionados à deficiência de estrogênio |
| US7595078B2 (en) * | 2005-03-15 | 2009-09-29 | Glanbia Nutritionals Ireland Limited | Methods of increasing flaxseed hull recovery and resultant flax products |
| JP2009520210A (ja) | 2005-12-19 | 2009-05-21 | アナリザ， インコーポレイテッド | スペクトルバイオマーカーのようなデータパターンに関するシステムおよび方法 |
| DE102006008772A1 (de) * | 2006-02-22 | 2007-08-23 | Beiersdorf Ag | Hydroxymatairesinol gegen trockene Haut |
| DE102006019044A1 (de) * | 2006-04-25 | 2007-10-31 | Merck Patent Gmbh | Antioxidantien |
| FI20106293A0 (fi) * | 2010-12-06 | 2010-12-06 | Emilia Peuhu | Uudet farmaseuttiset koostumukset |
| EP2517574B1 (de) | 2011-04-29 | 2015-11-11 | Symrise AG | Bestimmte Vanillyllignane und deren Verwendung als Geschmacksverbesserer |
| US10613087B2 (en) | 2012-08-10 | 2020-04-07 | Analiza, Inc. | Methods and devices for analyzing species to determine diseases |
| RU2510268C1 (ru) * | 2012-11-14 | 2014-03-27 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "Медресурс" | Средство для лечения эстрогензависимых опухолей |
| EP3142660B1 (de) | 2014-05-15 | 2019-08-21 | Linnea S.A. | Zusammensetzungen mit 7-hydroxymatairesinol |
| US9678076B2 (en) | 2014-06-24 | 2017-06-13 | Analiza, Inc. | Methods and devices for determining a disease state |
| CZ305794B6 (cs) * | 2015-04-20 | 2016-03-16 | Výzkumný ústav potravinářský Praha, v.v.i. | Způsob úpravy dřevních suků s přesně regulovanou strukturou drtě pro výrobu lignanů a zařízení k provádění tohoto způsobu, s využitím v potravinářské výrobě |
| US9669006B2 (en) | 2015-07-28 | 2017-06-06 | U.S. Nutraceuticals, LLC | Composition and method to treat and alleviate symptoms of hot flashes in a female subject |
| CA3008075A1 (en) * | 2015-12-09 | 2017-06-15 | Oy Granula Ab Ltd | The use of a composition for lowering cholesterol level in a mammal, a method for its preparation, a composition and a method for preparing food additive comprising said composition |
| IT201700050994A1 (it) * | 2017-05-11 | 2018-11-11 | Linnea Sa | Uso di una Composizione comprendente 7-Idrossimatairesinolo |
| WO2023076036A1 (en) | 2021-10-28 | 2023-05-04 | Analiza, Inc. | Partitioning systems and methods for determining multiple types of cancers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8628228D0 (en) * | 1986-11-26 | 1986-12-31 | Inst Biolog Morya Dalnevostoch | Composition inhibiting pathological addiction to alcohol |
| US4808674A (en) * | 1987-08-24 | 1989-02-28 | General Electric Company | Aryl ester-grafted polyphenylene ethers and phenylene ether-amide graft copolymers prepared therefrom |
| DE4317466A1 (de) | 1993-05-26 | 1994-12-01 | Degussa | Verbessertes Verfahren zur Bleiche von Holzstoffen |
| JPH10511699A (ja) | 1995-10-18 | 1998-11-10 | カノルト アルツナイミッテル ゲー エム ベー ハー | リグナン及びその製造方法並びに医薬組成物及びその使用方法 |
| WO1997032593A2 (en) | 1996-03-08 | 1997-09-12 | Energiser Plc | Composition containing iso-flavonoids and lignans |
| CA2201652C (en) | 1996-04-04 | 2007-09-11 | The University Of Saskatchewan | Use of purified sdg as an antioxidant |
| JP2987365B1 (ja) * | 1998-10-29 | 1999-12-06 | かどや製油株式会社 | 抗酸化剤 |
| CN1893939B (zh) * | 2003-12-26 | 2011-12-28 | 农工大Tlo株式会社 | 用于预防和治疗肝癌的组合物 |
-
1999
- 1999-03-30 US US09/281,094 patent/US6451849B1/en not_active Expired - Lifetime
-
2000
- 2000-03-09 CN CNB008055424A patent/CN1146553C/zh not_active Expired - Fee Related
- 2000-03-09 KR KR1020017012487A patent/KR100741724B1/ko not_active IP Right Cessation
- 2000-03-09 SK SK1326-2001A patent/SK287001B6/sk not_active IP Right Cessation
- 2000-03-09 HU HU0200530A patent/HUP0200530A3/hu unknown
- 2000-03-09 MX MXPA01009714A patent/MXPA01009714A/es active IP Right Grant
- 2000-03-09 KR KR1020077003673A patent/KR100741723B1/ko not_active IP Right Cessation
- 2000-03-09 DE DE60001271T patent/DE60001271T2/de not_active Expired - Lifetime
- 2000-03-09 AU AU31692/00A patent/AU767691B2/en not_active Ceased
- 2000-03-09 CZ CZ20100072A patent/CZ302730B6/cs not_active IP Right Cessation
- 2000-03-09 EP EP00909388A patent/EP1165537B1/de not_active Expired - Lifetime
- 2000-03-09 JP JP2000609455A patent/JP4852685B2/ja not_active Expired - Fee Related
- 2000-03-09 ES ES00909388T patent/ES2189738T3/es not_active Expired - Lifetime
- 2000-03-09 NZ NZ512099A patent/NZ512099A/xx not_active IP Right Cessation
- 2000-03-09 AT AT00909388T patent/ATE231500T1/de active
- 2000-03-09 CZ CZ20013486A patent/CZ301725B6/cs not_active IP Right Cessation
- 2000-03-09 EE EEP200100507A patent/EE200100507A/xx unknown
- 2000-03-09 SK SK5010-2009A patent/SK287749B6/sk not_active IP Right Cessation
- 2000-03-09 RU RU2001129166/15A patent/RU2241453C2/ru not_active IP Right Cessation
- 2000-03-09 CA CA2371839A patent/CA2371839C/en not_active Expired - Fee Related
- 2000-03-09 WO PCT/FI2000/000181 patent/WO2000059946A1/en active Application Filing
- 2000-03-09 CA CA2650297A patent/CA2650297C/en not_active Expired - Fee Related
- 2000-03-09 BR BR0007187-0A patent/BR0007187A/pt not_active Application Discontinuation
- 2000-03-09 DK DK00909388T patent/DK1165537T3/da active
- 2000-03-09 PL PL350367A patent/PL199892B1/pl unknown
-
2001
- 2001-04-11 US US09/829,944 patent/US20010016590A1/en not_active Abandoned
- 2001-05-30 ZA ZA200104440A patent/ZA200104440B/en unknown
- 2001-08-30 BG BG105856A patent/BG65380B1/bg unknown
- 2001-09-25 NO NO20014639A patent/NO330135B1/no not_active IP Right Cessation
-
2002
- 2002-10-08 HK HK02107351.6A patent/HK1045992B/zh not_active IP Right Cessation
-
2010
- 2010-07-27 NO NO20101067A patent/NO331188B1/no not_active IP Right Cessation
- 2010-12-06 NO NO20101701A patent/NO332110B1/no not_active IP Right Cessation
- 2010-12-16 JP JP2010280712A patent/JP2011052024A/ja active Pending
-
2011
- 2011-09-23 NO NO20111291A patent/NO332251B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60001271T2 (de) | Hydroxymatairesinol in der krebs-prevention | |
| IL130931A0 (en) | Small molecules useful in the treatment of inflammatory disease | |
| BR9811121A (pt) | Produto, composição farmacêutica, e uso de um produto | |
| WO2001036640A3 (en) | Human fgf-21 gene and gene expression products | |
| DE60235719D1 (de) | Frauenhygieneartikel zur verabreichung von arzneimittel | |
| HUP0102033A2 (hu) | PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére | |
| GB0109146D0 (en) | Treatment of type 2 diabetes | |
| WO2002040702A3 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
| FI963277A (fi) | Paramuunisuusinduktori, joka perustuu rokkoviruskomponenttien yhdistelmiin, menetelmä sen valmistamiseksi ja sen käyttö lääkeaineena | |
| WO2001076638A3 (en) | Compositions for drug delivery | |
| BR0110837A (pt) | Quimioterapia de combinação | |
| GB2368525A (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
| PT1150703E (pt) | Terapia de esclerose multipla com chaperonina 10 e beta-interferao | |
| MY103498A (en) | Dl-5-[(2-benzyl-3, 4-dihydro-2h-benzopyran-6-yl)methyl] thiazolidine-2, 4-dione as an anti-atherosclerosis agent | |
| ATE380555T1 (de) | Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng | |
| ZA200300675B (en) | Pharmaceutical preparation of the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma. | |
| IT1277118B1 (it) | Composizioni farmaceutiche per il trattamento delle epatopatie croniche | |
| NZ517348A (en) | Use of a mycobacterial extract in the treatment of inflammatory bowel disease | |
| MD1780G2 (ro) | Metodă de tratament al pacienţilor cu ciroze hepatice | |
| UA28489A (uk) | Спосіб лікування затримки статевого розвитку у хлопцівпідлітків | |
| PT1165596E (pt) | Derivados de 14,15-alfa-metileno equilenina processos para producao dos mesmos e medicamentos que os contem | |
| ZA991068B (en) | Novel disubstituted naphthyl derivatives, their preparation, pharmaceutical compositions which contain them and their use for the preparation of medicinal products. | |
| UA29106A (uk) | Спосіб лікування вібраційної хвороби | |
| WO2001035811A3 (en) | Methods of diagnosing and determining prognosis of breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |